Helgelandssykehuset HF
- Address
- Sjoeforsgata 36, 8613 Mo i Rana, Norway
Helgelandssykehuset HF - Rheumatology Research Center
Helgelandssykehuset HF is a medical research institution dedicated to advancing the treatment and management of rheumatologic conditions. The center specializes in innovative approaches to therapeutic drug monitoring and personalized medicine strategies for patients with chronic inflammatory diseases.
- Rheumatoid arthritis disease management and control
- Proactive therapeutic drug monitoring (TDM) for biologic therapies
- TNF inhibitor optimization and sustained remission strategies
The research center is particularly focused on optimizing treatment outcomes for rheumatoid arthritis patients receiving subcutaneous TNF inhibitors, investigating whether personalized dosing adjustments based on drug level monitoring can improve long-term disease control and prevent disease flares compared to conventional treatment approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Helgelandssykehuset HF
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Proactive Therapeutic Drug Monitoring Versus Standard Care in Sustaining Disease Control in Rheumatoid Arthritis Patients on Subcutaneous Adalimumab | Diakonhjemmet Sykehus AS, Humanitas Mirasole S.p.A., Karolinska University Hospital, Medical University Of Vienna, University Of Medicine And Pharmacy Carol Davila Bucharest | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2024-08-20 | 2024-08-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.